Icon (NASDAQ:ICLR) Releases FY 2025 Earnings Guidance

Key Points

• Icon (NASDAQ:ICLR) issued FY 2025 earnings guidance, forecasting an EPS range of 13.000-14.000 and revenue between $7.9 billion to $8.2 billion, surpassing consensus estimates.
• Brokerage upgrades include Evercore ISI raising its target price from $170.00 to $240.00 and Rothschild Redb changing its rating from "hold" to "strong-buy."
• Icon's stock has shown resilience with a market capitalization of $13.36 billion and the current trading price opens at $165.44, near its fifty-two week high of $310.54.

Icon (NASDAQ:ICLR - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 13.000-14.000 for the period, compared to the consensus EPS estimate of 13.020. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $8.0 billion.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ICLR. Evercore ISI increased their target price on shares of Icon from $170.00 to $240.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Rothschild Redb upgraded shares of Icon from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 3rd. Robert W. Baird increased their price target on shares of Icon from $222.00 to $224.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 2nd. Citigroup reiterated a "neutral" rating and set a $200.00 price target (down previously from $225.00) on shares of Icon in a research report on Thursday, August 21st. Finally, Jefferies Financial Group lowered shares of Icon from a "buy" rating to a "hold" rating and reduced their price target for the stock from $220.00 to $175.00 in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and seven have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $216.67.

Icon Stock Performance

Shares of Icon stock opened at $165.44 on Thursday. Icon has a fifty-two week low of $125.10 and a fifty-two week high of $310.54. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.29 and a quick ratio of 1.29. The firm has a market capitalization of $13.36 billion, a P/E ratio of 17.02, a P/E/G ratio of 2.50 and a beta of 1.20. The company's 50 day moving average price is $166.87 and its two-hundred day moving average price is $158.29.

Icon (NASDAQ:ICLR - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share for the quarter, beating analysts' consensus estimates of $3.18 by $0.08. Icon had a net margin of 9.82% and a return on equity of 10.95%. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $1.98 billion. During the same quarter last year, the business posted $3.75 earnings per share. The company's quarterly revenue was down 4.8% on a year-over-year basis. Icon has set its FY 2025 guidance at 13.000-14.000 EPS. On average, equities analysts forecast that Icon will post 13.38 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Icon

Large investors have recently modified their holdings of the business. Daiwa Securities Group Inc. raised its stake in shares of Icon by 19.3% during the second quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company's stock valued at $4,094,000 after acquiring an additional 4,546 shares during the last quarter. Manhattan West Asset Management LLC raised its stake in Icon by 23.7% during the second quarter. Manhattan West Asset Management LLC now owns 20,588 shares of the medical research company's stock worth $2,995,000 after buying an additional 3,948 shares during the last quarter. Two Sigma Securities LLC raised its stake in Icon by 178.5% during the second quarter. Two Sigma Securities LLC now owns 7,272 shares of the medical research company's stock worth $1,058,000 after buying an additional 4,661 shares during the last quarter. SkyView Investment Advisors LLC raised its stake in Icon by 1.8% during the second quarter. SkyView Investment Advisors LLC now owns 6,321 shares of the medical research company's stock worth $914,000 after buying an additional 113 shares during the last quarter. Finally, Militia Capital Partners LP bought a new position in Icon during the second quarter worth $873,000. Institutional investors own 95.61% of the company's stock.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.